Results: According to NGS results, mutations were detected in EGFR (52/111, 46, 8% of patients), KRAS (16/111, 14, 4%), BRAF (5/111, 4, 5%), ALK (3/111, 2, 7%), ROS1 (2/111, 1.8%), BRAF-NRAS (1/111, 0, 9%) and ALK-BRAF (1/111, 0, 9%) Conclusions: NGS allows for specific detection and precise identification of gene mutations in NSCLC patients.